The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613

Clinical Lung Cancer

Volumn 18, Issue 5, 2017, Pages 583-588

  Remon, Jordi ^a   Menis, Jessica ^b   Hasan, Baktiar ^b   Peric, Aleksandra ^b   De Maio, Eleonora ^b   Novello, Silvia ^c   Reck, Martin ^d   Berghmans, Thierry ^e   Wasag, Bartosz ^f,g   Besse, Benjamin ^a,b   Dziadziuszko, Rafal ^f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY OF TURIN   (Italy)

^d GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^e JULES BORDET INSTITUTE   (Belgium)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g Department of Urology   (Poland)

Author keywords

AZD9291; Blood; EGFR mutation; Gefitinib; Lung

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; METHIONINE; OSIMERTINIB; THREONINE; ANTINEOPLASTIC AGENT; DNA; PIPERAZINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; FEASIBILITY STUDY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDY; TRANSLATIONAL RESEARCH; BLOOD; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; GENETICS; LIQUID BIOPSY; LUNG TUMOR; METHODOLOGY; MUTATION; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; DRUG SUBSTITUTION; FEASIBILITY STUDIES; HUMANS; LIQUID BIOPSY; LUNG NEOPLASMS; MUTATION; PIPERAZINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 85015727416     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2017.02.005     Document Type: Article

References (36)

1. Midha, A., Dearden, S., McCormack, R., EGFR mutation incidence in non–small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5 (2015), 2892–2911.
2. Barlesi, F., Mazieres, J., Merlio, J.P., et al. Routine molecular profiling of patients with advanced non–small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387 (2016), 1415–1426.
3. Reguart, N., Remon, J., Common EGFR-mutated subgroups (Del19/L858R) in advanced non–small-cell lung cancer: chasing better outcomes with tyrosine-kinase inhibitors. Future Oncol 11 (2015), 1245–1257.
4. Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3, 2011, 75ra26.
5. Arcila, M.E., Oxnard, G.R., Nafa, K., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17 (2011), 1169–1180.
6. Yu, H.A., Arcila, M.E., Rekhtman, N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19 (2013), 2240–2247.
7. Cross, D.A., Ashton, S.E., Ghiorghiu, S., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4 (2014), 1046–1061.
8. Ballard, P., Yates, J.W., Yang, Z., et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22 (2016), 5130–5140.
9. Yang JC, Kim DW, Kim SW, et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non–small-cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. ASCO Meeting Abstracts 2016; 34(15 suppl):9002.
10. Jänne, P.A., Yang, J.C., Kim, D.W., et al. AZD9291 in EGFR inhibitor-resistant non–small-cell lung cancer. N Engl J Med 372 (2015), 1689–1699.
11. Oxnard, G.R., Thress, K.S., Alden, R.S., et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer. J Clin Oncol 34 (2016), 3375–3382.
12. Yang, J., Ahn, M., Ramalingam, S., et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study phase II extension cohort. J Thorac Oncol, 10(9 suppl 2), 2015, S319.
13. Mitsudomi, T., Tsai, C.M., Shepherd, F., et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 phase II study. J Thorac Oncol, 10(9 suppl 2), 2015, S320.
14. Mok, T.S., Wu, Y.L., Ahn, M.J., et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376 (2017), 629–640.
15. FDA. US Food & Drug Administration. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.
16. TAGRISSO Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004124/WC500202022.pdf.
17. Ramalingam, S., Yang, J.C., Lee, C.K., et al. Osimertinib as first-line treatment for EGFR-mutation-positive advanced NSCLC: updated efficacy and safety results from two phase I expansion cohorts. J Thorac Oncol, 11(4 suppl), 2016, S152.
18. Mok, T.S., Wu, Y.L., Thongprasert, S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (2009), 947–957.
19. Sequist, L.V., Yang, J.C., Yamamoto, N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31 (2013), 3327–3334.
20. Remon J, Faivre L, Facchinetti F, et al. Radiogenomics in 332 metastatic non–small-cell lung cancer (NSCLC) patients. ASCO Meeting Abstracts 2016; 34(15 suppl):11563.
21. Bosc, C., Ferretti, G.R., Cadranel, J., et al. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. Target Oncol 10 (2015), 247–253.
22. Piotrowska, Z., Nierdest, M.J., Mino-Kenudson, M., et al. Variation in mechanisms of acquired resistance among EGFR-mutant NSCLC patients with more than 1 postresistance biopsy. Int J Radiat Oncol 90 (2014), S6–S7.
23. Sundaresan, T.K., Sequist, L.V., Heymach, J.V., et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res 22 (2016), 1103–1110.
24. Hata, A., Katakami, N., Yoshioka, H., et al. Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non–small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol 10 (2015), 1553–1559.
25. Jovelet, C., Ileana, E., Le Deley, M.C., et al. Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial. Clin Cancer Res 22 (2016), 2960–2968.
26. Marchetti, A., Palma, J.F., Felicioni, L., et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol 10 (2015), 1437–1443.
27. Mok, T., Wu, Y.L., Lee, J.S., et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 21 (2015), 3196–3203.
28. Sorensen, B.S., Wu, L., Wei, W., et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small-cell lung cancer during treatment with erlotinib. Cancer 120 (2014), 3896–3901.
29. Murtaza, M., Dawson, S.J., Pogrebniak, K., et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun, 6, 2015, 8760.
30. Soria, J.C., Wu, Y.L., Nakagawa, K., et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non–small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 16 (2015), 990–998.
31. Remon, J., Caramella, C., Jovelet, C., et al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA [e-pub ahead of print]. Ann Oncol, 2017, 10.1093/annonc/mdx017.
32. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New Response Evaluation Criteria In Solid Tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
33. Park, K., Yu, C.J., Kim, S.W., et al. First-line erlotinib therapy until and beyond Response Evaluation Criteria in Solid Tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non–small-cell lung cancer: the ASPIRATION study. JAMA Oncol 2 (2016), 305–312.
34. Schuler, M., Yang, J.C., Park, K., et al. Afatinib beyond progression in patients with non–small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 27 (2016), 417–423.
35. Katakami, N., Atagi, S., Goto, K., et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non–small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31 (2013), 3335–3341.
36. Miller, V.A., Hirsh, V., Cadranel, J., et al. Afatinib versus placebo for patients with advanced, metastatic non–small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13 (2012), 528–538.